PL1901773T3 - Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu - Google Patents
Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepuInfo
- Publication number
- PL1901773T3 PL1901773T3 PL06754207T PL06754207T PL1901773T3 PL 1901773 T3 PL1901773 T3 PL 1901773T3 PL 06754207 T PL06754207 T PL 06754207T PL 06754207 T PL06754207 T PL 06754207T PL 1901773 T3 PL1901773 T3 PL 1901773T3
- Authority
- PL
- Poland
- Prior art keywords
- ides
- pyogenes
- proteinase
- autoimmune diseases
- graft rejection
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 241000193996 Streptococcus pyogenes Species 0.000 title 1
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0511769A GB0511769D0 (en) | 2005-06-09 | 2005-06-09 | Treatment |
| GB0605781A GB0605781D0 (en) | 2006-03-22 | 2006-03-22 | Treatment |
| PCT/EP2006/005454 WO2006131347A2 (en) | 2005-06-09 | 2006-06-08 | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| EP06754207A EP1901773B1 (en) | 2005-06-09 | 2006-06-08 | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1901773T3 true PL1901773T3 (pl) | 2012-09-28 |
Family
ID=36952007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06754207T PL1901773T3 (pl) | 2005-06-09 | 2006-06-08 | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8133483B2 (pl) |
| EP (1) | EP1901773B1 (pl) |
| JP (1) | JP5427409B2 (pl) |
| CN (1) | CN105770871A (pl) |
| AT (1) | ATE548049T1 (pl) |
| AU (1) | AU2006256891B2 (pl) |
| BE (1) | BE2021C505I2 (pl) |
| CA (1) | CA2611646C (pl) |
| ES (1) | ES2380950T3 (pl) |
| FR (1) | FR21C1004I2 (pl) |
| NL (1) | NL301089I2 (pl) |
| PL (1) | PL1901773T3 (pl) |
| PT (1) | PT1901773E (pl) |
| WO (1) | WO2006131347A2 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595057B2 (en) * | 2000-12-21 | 2009-09-29 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| US8691544B2 (en) | 2007-05-04 | 2014-04-08 | Glycorex Transplantation Ab | Material for separation of a biomolecule |
| WO2009080278A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Stability testing of antibodies |
| CN102308216B (zh) | 2009-02-09 | 2014-07-09 | 罗切格利卡特公司 | 免疫球蛋白糖基化模式分析 |
| CA2741965A1 (en) * | 2009-04-22 | 2010-10-28 | Ofir Menashe | Microorganism comprising particles and uses of same |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US12006530B2 (en) * | 2016-02-04 | 2024-06-11 | Genovis Ab | Streptococcal proteases |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CA3149395A1 (en) * | 2019-08-01 | 2021-02-04 | Memorial Sloan-Kettering Cancer Center | Cells for improved immunotherapy and uses thereof |
| US11186625B2 (en) | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| CN120078887A (zh) * | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| JP2023545731A (ja) | 2020-10-07 | 2023-10-31 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| CN118382454B (zh) * | 2021-12-22 | 2025-10-31 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体的用途 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| CN120677180A (zh) | 2022-11-18 | 2025-09-19 | 赛斯米克治疗公司 | Fc融合分子及其用途 |
| US12129499B2 (en) | 2023-01-06 | 2024-10-29 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025030053A1 (en) * | 2023-08-01 | 2025-02-06 | Insmed Incorporated | Novel igg proteases and methods of use thereof |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797263B2 (en) * | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2006
- 2006-06-08 EP EP06754207A patent/EP1901773B1/en active Active
- 2006-06-08 WO PCT/EP2006/005454 patent/WO2006131347A2/en not_active Ceased
- 2006-06-08 JP JP2008515137A patent/JP5427409B2/ja active Active
- 2006-06-08 US US11/921,770 patent/US8133483B2/en active Active
- 2006-06-08 ES ES06754207T patent/ES2380950T3/es active Active
- 2006-06-08 PT PT06754207T patent/PT1901773E/pt unknown
- 2006-06-08 CA CA2611646A patent/CA2611646C/en active Active
- 2006-06-08 AT AT06754207T patent/ATE548049T1/de active
- 2006-06-08 PL PL06754207T patent/PL1901773T3/pl unknown
- 2006-06-08 AU AU2006256891A patent/AU2006256891B2/en active Active
- 2006-06-08 CN CN201610049256.0A patent/CN105770871A/zh active Pending
-
2021
- 2021-01-14 NL NL301089C patent/NL301089I2/nl unknown
- 2021-02-04 FR FR21C1004C patent/FR21C1004I2/fr active Active
- 2021-02-09 BE BE2021C505C patent/BE2021C505I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1901773B1 (en) | 2012-03-07 |
| BE2021C505I2 (pl) | 2021-05-31 |
| AU2006256891B2 (en) | 2011-08-04 |
| NL301089I2 (nl) | 2021-02-04 |
| US8133483B2 (en) | 2012-03-13 |
| PT1901773E (pt) | 2012-06-06 |
| EP1901773A2 (en) | 2008-03-26 |
| AU2006256891A1 (en) | 2006-12-14 |
| US20100303781A1 (en) | 2010-12-02 |
| FR21C1004I2 (fr) | 2022-01-14 |
| ATE548049T1 (de) | 2012-03-15 |
| CN105770871A (zh) | 2016-07-20 |
| ES2380950T3 (es) | 2012-05-21 |
| JP2008542418A (ja) | 2008-11-27 |
| NL301089I1 (pl) | 2021-01-20 |
| JP5427409B2 (ja) | 2014-02-26 |
| WO2006131347A2 (en) | 2006-12-14 |
| CA2611646A1 (en) | 2006-12-14 |
| WO2006131347A3 (en) | 2007-05-31 |
| CA2611646C (en) | 2015-08-11 |
| FR21C1004I1 (pl) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1004I2 (fr) | Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe | |
| WO2008071418A3 (en) | Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases | |
| TW200709817A (en) | Platform antibody compositions | |
| WO2004108895A3 (en) | Humanized antibodies that recognize beta amyloid peptide | |
| WO2007044756A3 (en) | Monoclonal antibodies recognizing human ccr8 | |
| WO2003048327A3 (en) | Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection | |
| WO2006127757A3 (en) | Interferon-igg fusion | |
| TW200635608A (en) | Aβ antibodies for use in improving cognition | |
| TW200635607A (en) | Humanized Aβ antibodies for use in improving cognition | |
| TW200740844A (en) | Novel MAdCAM antibodies | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
| MY149630A (en) | Antibodies against amyloid-beta peptide | |
| WO2005072223A3 (en) | Engineered proteins, and methods of making and using | |
| WO2005061544A3 (en) | Nogo-a neutralising immunoglobulins for treatment of neurological diseases | |
| SG171599A1 (en) | Blood group antigens of different types for diagnostic and therapeutic applications | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| MY149492A (en) | Immunoglobulins directed against nogo | |
| SG170804A1 (en) | Pseudomonas aeruginosa outer membrane protein pa0427 | |
| ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
| NO20064896L (no) | Fremgangsmater for behandling av autoimmune og inflammatoriske sykdommer | |
| WO2005071067A3 (en) | Non-animal origin stabilizers and processes for producing the same | |
| GB0300718D0 (en) | Proteins | |
| WO2004074436A3 (en) | Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer | |
| WO2007101988A3 (en) | Use of tsg-6 for treating bone diseases |